EGFR and prostate carcinoma: Furthermore, osimertinib promotes exosome release via upregulating RAB17 and exosome‐mediated intercellular transfer of wild‐type EGFR protein to EGFR‐mutant cancer cells, thus activating downstream PI3K/Akt and MAPK signaling pathways and promoting osimertinib resistance.[70] Lee et al. suggest that yes‐associated protein 1 (YAP1) is upregulated in prostate cancer cells with resistance to enzalutamide (EzaR), an androgen receptor inhibitor.